Intrexon, Oragenics deal

Oragenics and Intrexon partnered to develop and commercialize genetically modified probiotics to treat diseases of the oral cavity, throat, sinus and esophagus, with an initial focus on Behcet's disease and aphthous stomatitis. Intrexon will be responsible for technology discovery, cell-engineering development, and parts of the manufacturing process. Oragenics will be responsible for all development and commercialization of products resulting from the deal. ...